ZENITHEPIGENETICS

We are a clinical-stage biotechnology company developing best-in-class bromodomain and extra-terminal inhibitors (BETi) for the treatment of multiple cancers and other disorders with significant unmet medical need. Our goal is to be a leading oncology company in the field of epigenetics, translating bromodomain biology into impactful, targeted therapeutics for the benefit of patients... Zenith Epigenetics' experienced research team has developed a cutting-edge epigenetic platform, generating differentiated, potent, and selective BET inhibitors. Our experienced management team and world-leading clinical collaborators are developing BETi combination therapies for multiple oncology indications. With a strong emphasis on translational medicine - for selecting patients that will benefit most from the therapy - Zenith is a leader in innovative clinical development of epigenetic combination therapies.

Also known as: Zenith Capital Corp., Zenith Epigenetics Ltd.

Primary location: San Francisco United States